Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An inspiring doctor and scientist of great compassion and intellect, Sir David Weatherall died 8 Dec 2018. A Nuffield Professor of Medicine, founder of the MRC Weatherall Institute of Molecular Medicine and a member of Wellcome’s Board throughout the 1990s, Sir David was instrumental in the creation of MORU back in 1979.

David Weatherall © Credit: University of Exeter CC BY 2.0

Personal Note from Nick White, SE Asia Chairman, MORU Tropical Network

Professor David Weatherall had the greatest influence on my professional life and for that I will be eternally grateful. I went to work for him as a young medical registrar at the Radcliffe Infirmary in Oxford in November 1977 (Tim Peto was my houseman!). Before I went to Oxford I had never heard of him – a reflection of my ignorance as he was already recognised as a brilliant scientist and an emerging leader in British academic medicine. I first met him (we all called him “Prof”) in his book lined office with old leathery chairs and a thick haze of aromatic pipe smoke. I said I wanted to work in the tropics one day, and he told me that he too was interested in tropical medicine and, if possible, would make it happen. He certainly did, and that is why we have a 40 year medical research collaboration based in Thailand and a younger unit in Vietnam.

“Prof” was a brilliant scientist and a perceptive, wise, witty, gentle, compassionate and inspiring physician. He would always enquire about his patient’s social circumstances, and he always examined them. This was an era when senior physicians and surgeons often felt and acted as if they were on a higher plane than the remainder of humanity. David Weatherall hated all that pomp and flummery. He treated everyone as equals. He had a sharp wit, an open and enquiring mind, and he took genuine satisfaction and pride in the success of others. “Prof” inspired and supported a generation of young physicians and scientists. He became the UK’s leading academic clinician, a towering figure in the molecular medicine revolution, an internationally acclaimed scientist, and he was showered with honours and accolades – but his character never changed.

In the late 1970s the Wellcome Trust were seeking to set up a new tropical medicine research unit in East Asia. David Weatherall and Peter Williams (then the Director of the Wellcome Trust) visited several potential collaborating institutions. The Faculty of Tropical Medicine, Mahidol University were interested in this idea and so the Bangkok unit began in 1979 as a collaboration between the Faculty and the Nuffield Department of Medicine, Oxford University headed by David Weatherall. David and Mary Warrell came out to start the research work and I joined them the following year. “Prof” supported us through good times and bad, and although we were successful on the scientific front there were bad times too. We came under a lot of pressure in the late 1980s and I thought we might have to close the Unit and leave Thailand. This led to the founding of the Vietnam unit. David Weatherall in Oxford and Bridget Ogilvie at the Wellcome Trust gave us unwavering support throughout those hard times. Without that we would not have MORU today.

I kept “Prof” up to date with everything that happened in our Unit, and our research progress because he was always interested and encouraging, and he invariably gave wise advice. For such a brilliant mind he was interestingly averse to communications technology – he never mastered computers or e-mail, preferring written letters and personal meetings. As far as I know he never possessed a mobile ‘phone! In scientific and clinical meetings, he would close his eyes, and appear to be completely asleep, but as soon as the speaker stopped he would open his eyes and ask pertinent questions! He was a determined pipe smoker – and on two occasions I witnessed smoke billowing from the pocket of his white coat! Long after he retired I would visit him whenever I was in Oxford to report as he wanted to know how we in MORU were getting on, what advances we had made, and whether there was anything he could do to help. He had a great affection for Thailand, sharing research interests on the study and management of haemoglobinopathies, collaborating with leading figures in Thai medical research, and later advising the Prince Mahidol Award foundation. He was very happy to see the research progress, and particularly the translation to human benefit, and also the career progression of young investigators from Thailand and neighbouring countries. We certainly owe him a lot.

He was a very great man.

Read Sir David’s recollections of how MORU came about (pdf)

Read the News "Sir David Weatherall, 1933-2018" on the Wellcome website

Read what the University of Oxford says about Sir David’s remarkable career.

Similar stories

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Professors Peter Horby and Guy Thwaites recognised in Queen’s Birthday Honours

The pioneering work of members of the University of Oxford has been recognised in The Queen's Birthday Honours List. The honorands include Professor Peter Horby and six researchers that have played key roles in leading the University’s response to the Coronavirus pandemic, from the development of new vaccines to the discovery of new drug treatments. Professor Guy Thwaites is appointed a Member of the Order of the British Empire.

RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with COVID-19. Patients with COVID-19 are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly 15,000 patients hospitalised with COVID-19 in an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases. There was no significant difference in the primary endpoint of 28-day mortality

The COVID-19 International Modelling Consortium (CoMo Consortium) enters a new phase

Created in March 2020 to assist policymakers to make use of existing evidence in mathematical and epidemiological models to inform strategies for minimising the impact of COVID-19, the CoMo Consortium brings together mathematical modellers, epidemiologists, health economists and public health experts from more than 40 countries across Africa, Asia and South and North America.

ASM Editor in conversation with Nick White

Malaria continues to be a major killer, particularly in sub-Saharan Africa, affecting the world’s most vulnerable populations with more than 500,000 deaths per year, most of them African children. Emergence of resistance to antimalarial drugs is major public health issue. American Society for Microbiology Editor Dr Cesar Arias discusses with Professor Sir Nick White the latest information on this rapidly evolving field.

New Pandemic Sciences Centre at the University of Oxford

The University of Oxford announces the launch of a centre of global research collaboration and excellence, the Pandemic Sciences Centre. The need for partnership between academic excellence, industry and public health organisations is one of the key lessons learned from the coronavirus pandemic. This centre will unite disciplines, and sectors, to build agile, equitable partnerships that can tackle complex problems and respond to pandemic threats at any time.